Assessment of the Levels of Interleukin-6, Interleukin-10, and Leukemia Inhibitory Factor in Patients with Acute Myeloid Leukemia in Dhi Qar Governorate
DOI:
https://doi.org/10.36320/ajb/v16.i2.16364Keywords:
Keywords: Biochemical parameters, Immunity response, AML, Iraqi patientsAbstract
Abstract: Acute myeloid leukaemia (AML) is a bone marrow-originating form of leukaemia that is capable of metastasizing to multiple organs. The purpose of the study was to investigate the role of serum biomarkers associated with immune responses that fluctuate in Iraqi patients with AML and to assess the changes in these biomarkers. The present study enrolled a total of 100 participants, including 50 males and 50 females, of which 50 had been identified as having AML and the remaining 50 were in good health. Serum levels of leukaemia inhibitory factor (LIF), interleukin-6 (IL-6), and interleukin-10 (IL-10) were estimated in patients with AML. The findings indicated that serum concentrations of IL-6, IL-10, and LIF were significantly elevated (p<0.05) in patients with AML relative to healthy individuals. The results provide evidence in favor of the view that the these biomarkers might play a substantial role in the advancement of AML.
Downloads
References
Cancer council Australia (CCA) (2019). Cancer biology: Molecular and genetic basis. Australia.
American Cancer Society (ACS) (2023). Cancer Facts & Figures 2023.4th Edition. American Cancer Society report, Atlanta. USA. cancer.org| 1.800.227.2345.
Iraqi Cancer Board (ICB) (2020). Iraq Cancer Registry for 2020 report. Ministry of Health and Environment, Iraq.
American Cancer Society (ACS) (2018). About Acute Myeloid Leukemia (AML). American Cancer Society report, Atlanta. USA. cancer.org| 1.800.227.2345.
Pradhan, R., Kundu, A., & Kundu, C. N. (2024). The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth. Critical Reviews in Oncology/Hematology, 196:104311
Zaporowska-Stachowiak, I., Springer, M., Stachowiak, K., Oduah, M., Sopata, M., Wieczorowska-Tobis, K., & Bryl, W. (2024). Interleukin-6 family of cytokines in cancers. Journal of Interferon and Cytokine Research, 44(2):45-59.
Yahya, D. J., Al-Maaroof, Z. W., & Hassoon, A. F. (2016). Evaluation of leukemia inhibitory factor, interleukin 6 and leptin in acute and chronic myeloid leukemia in Babylon Province. Medical Journal of Babylon, 13(2):513-521.
Binder, S., Luciano, M., & Horejs-Hoeck, J. (2018). The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. Cytokine & Growth Factor Reviews, 43:8-15.
Theml, H., Diem, H., & Haferlach, T. (2004). Color Atlas of Hematology: Practical Microscopic and Clinical Diagnosis. Thieme New York, 333 Seventh Avenue, New York, NY 10001 USA.
Abdel-Hafez, Z., Abdou, M.A., Ahmed, T. S., & Salah El-din, M. M. (2018). Assessment of the serum level of interleukin-6 and interleukin-10 in newly diagnosed acute myeloid leukemia patients and the response to induction chemotherapy. Med. J. Cairo Univ., 86(3):1565-1572.
Mahmood, E. F. & Ahmed, A.A. (2020). Evaluation of interleukin‑35 and interleukin‑10 in adult acute myeloid leukemia patients before and after induction chemotherapy. Iraqi Journal of Hematology, 9:82-86.
Ali, K. A., Mohammad, H. A., Naji, A. S., & Alwan, A. F. (2022). Serum hepcidin levels related to interlukin-6 in patients with acute myeloid leukemia before and after treatment. Iraqi Journal of Hematology, 11(1):76-82.
Kaser, E. C., Zhao, L., D’mello, K. P., Zhu, Z., Xiao, H., Wakefield, M. R., Fang, Y. et al. (2021). The role of various interleukins in acute myeloid leukemia. Medical Oncology, 38:1-6.
Luciano, M., Krenn, P. W., & Horejs-Hoeck, J. (2022). The cytokine network in acute myeloid leukemia. Frontiers in Immunology, 13:1-13.
Wang, Y., Tang, X., Zhu, Y., Yang, X., & Liu, B. (2023). Role of interleukins in acute myeloid leukemia. Leukemia and Lymphoma, 64(8):1400-1413.
Sooreshjani, M., Tripathi, S., Dussold, C., Najem, H., de Groot, J., Lukas, R. V., & Heimberger, A. B. (2023). The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma. Cancers, 15:1-17.
Sariani, O. K., Eghbalpour, S., Kazemi, E., Buzhani, K. R., & Zaker, F. (2021). Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine, 142:1-10.
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021). Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 21(8):481-499.
Ahmed, H. S., Tahir, N. T., & Obed, F. A. (2017). Cytokines profiling as prognostic markers in newly diagnosed acute myeloid leukemia. Iraqi Journal of Hematology, 6(2):65-68.
Rašková, M.; Lacina, L.; Kejík, Z.; Venhauerová, A.; Skalicˇková, M.; Kolárˇ, et al. (2022). The Role of IL-6 in cancer cell invasiveness and metastasis—overview and therapeutic opportunities. Cells, 11:2-23
Dawood, S. D. (2011). Assessment of IL-6 serum level in patients with acute myeloid leukemia. Iraqi J. Cancer Med. Genet., 4:22-28.
Yacoub M.F., Ferwiz H.F., & Said F. (2020). Effect of interleukin and hepcidin in anemia of chronic diseases. Anemia, 2020:1-5.
Carlini, V., Noonan, D.M., Abdalalem, E., Goletti, D., Sansone, C.; Calabrone, L., Albini, A. (2023). The multifaceted nature of IL-10: Regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol., 14: 1-19.
Musuraca G., De Matteis S., Napolitano R., Papayannidis C., Guadagnuolo V., Fabbri F., et al. (2015). IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. J. Transl. Med., 3:1-10.
Alizadeh, S., Bohloli, S., Abedi, A., Mousavi, S. H., Dargahi, H., Jafarzadeh, et al. (1997). Investigation of leptin, leukemia inhibitory factor (LIF), and IL-6 serum levels in myeloid leukemia. IJBC, 2:36-77.
Jorgensen, M. M., & de la Puente, P. (2022). Leukemia inhibitory factor: an important cytokine in pathologies and cancer. Biomolecules, 12(2):2-23.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Sarah musa, Abdulhadi Alibraheemi
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
